Severe Anemia Secondary to a Probable Drug Interaction between Zidovudine and Valproic Acid
Open Access
- 1 March 2004
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (5) , e38-e40
- https://doi.org/10.1086/381760
Abstract
A 42-year-old man with human immunodeficiency virus (HIV) infection and a history of complex partial seizures developed severe anemia after the addition of valproic acid to his stable antiretroviral regimen of zidovudine, lamivudine, and abacavir. The inhibition of zidovudine glucuronidation by valproic acid and the resultant zidovudine hematologic toxicity is the proposed mechanism of the interaction.Keywords
This publication has 13 references indexed in Scilit:
- The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferasesBiochemical Pharmacology, 2003
- The bottleneck in AZT activationNature Medicine, 1997
- The effect of zidovudine dose on the formation of intracellular phosphorylated metabolitesAIDS, 1996
- 3′-Azidothymidine (Zidovudine) Inhibits Glycosylation and Dramatically Alters Glycosphingolipid Synthesis in Whole Cells at Clinically Relevant ConcentrationsPublished by Elsevier ,1995
- Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas antihuman immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cellsBiochemical Pharmacology, 1995
- Risk and Protective Factors in the Development of PsychopathologyAmerican Journal of Psychiatry, 1995
- Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virusClinical Pharmacology & Therapeutics, 1994
- 3'-azido-3'-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNAAntimicrobial Agents and Chemotherapy, 1993
- Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50 x 10(9)/L or less. Detailed and updated results from protocol 019 of the AIDS Clinical Trials GroupArchives of internal medicine (1960), 1992
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981